home / stock / mrns / mrns articles

MRNS Articles, Marinus Pharmaceuticals Inc. - From 06/21/24

Stock Information
Company Name: Marinus Pharmaceuticals Inc.
Stock Symbol: MRNS
Market: NASDAQ
Website: marinuspharma.com
Menu
MRNS MRNS Quote MRNS Short MRNS News MRNS Articles MRNS Message Board
Get MRNS Alerts

News, Short Squeeze, Breakout and More Instantly...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Lamb Weston, and Teradata and Encourages Investors to Contact the Firm | Benzinga

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...
MRNS Class Action Alert: Robbins LLP Reminds MRNS Stockholders About the Marinus Pharmaceuticals, Inc. Securities Fraud Class Action | Benzinga

SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and ent...

DEADLINE ALERT for MRNS, SMG, and GRTS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga

LOS ANGELES, June 20, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – MRNS | Benzinga

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ma...
Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients | Benzinga

Monday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced topline results from the Phase 3 RAISE trial evaluating the safety and efficacy of intr...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Autodesk, and Marinus and Encourages Investors to Contact the Firm | Benzinga

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds invest...

INVESTOR ALERT: Edelson Lechtzin LLP Urges Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Shareholders to Consult Counsel About the Pending Securities Fraud Class Action | Benzinga

NEWTOWN, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims ...
DEADLINE ALERT for MRNS and GRTS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | Benzinga

LOS ANGELES, June 14, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on ...

Avidity Up 33% on Rare Muscle Disease Study Results | Benzinga

Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlo...

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS | Benzinga

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, ...
Previous 10 Next 10